HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Revolution Medicines, Inc.

Contributing Author

Recent Articles by Revolution Medicines, Inc.

Jun-30
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors RVMD GlobeNewswire
Jun-24
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers RVMD GlobeNewswire
Jun-23
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations RVMD GlobeNewswire
May-14
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer RVMD GlobeNewswire
May-07
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite